Skip to main content

Macular Edema

30
Pipeline Programs
20
Companies
37
Clinical Trials
1 recruiting
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
1
8
0
13
5
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
6100%
+ 43 programs with unclassified modality

On Market (2)

Approved therapies currently available

AbbVie
OZURDEXApproved
dexamethasone
AbbVie
Corticosteroid [EPC]intravitreal2009
2M Part D
AbbVie
AEROSEB-DEXApproved
dexamethasone
AbbVie
topical

Competitive Landscape

20 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
19 programs
1
4
5
3
OZURDEXPhase 41 trial
Ozurdex Intravitreal InjectionPhase 41 trial
dexamethasone implantPhase 41 trial
700 µg DexamethasonePhase 31 trial
700 µg DexamethasonePhase 31 trial
+14 more programs
Active Trials
NCT01805323Completed101Est. Apr 2013
NCT01945892Completed23Est. Jul 2013
NCT01571557Completed573Est. Jun 2014
+16 more trials
Sandoz
SandozAustria - Kundl
5 programs
2
3
Ranibizumab 0.5 mg/0.05 mlPhase 3
Ranibizumab 0.5mgPhase 3
ranibizumabPhase 3Monoclonal Antibody
LKA651Phase 1
MHU650Phase 1
Clearside Biomedical
Clearside BiomedicalGA - Alpharetta
3 programs
1
2
suprachoroidal CLS-TAPhase 31 trial
suprachoroidal CLS-TAPhase 31 trial
4 mg CLS-TAPhase 21 trial
Active Trials
NCT02303184Completed46Est. Mar 2016
NCT03203447Terminated325Est. Dec 2018
NCT02980874Terminated460Est. Dec 2018
Kodiak Sciences
Kodiak SciencesCA - Palo Alto
1 program
1
KSI-301Phase 31 trial
Active Trials
NCT04592419Completed568Est. Jan 2023
Bayer
BayerLEVERKUSEN, Germany
1 program
1
VEGF Trap-EyePhase 31 trial
Active Trials
NCT01512966Completed73Est. Sep 2013
Pfizer
PfizerNEW YORK, NY
1 program
1
pegaptanib sodiumPhase 31 trial
Active Trials
NCT01100307Completed243Est. Aug 2012
Alcon
AlconFORT WORTH, TX
1 program
1
Nepafenac ophthalmic suspension, 0.1%Phase 21 trial
Active Trials
NCT00782717Completed263Est. Jul 2010
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
triamcinolone acetonidePhase 2
MSD
MSDIreland - Ballydine
1 program
1
triamcinolone acetonidePhase 21 trial
Active Trials
NCT00692614Terminated2Est. Nov 2008
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
GSK2798745Phase 1
Kubota Vision
Kubota VisionJapan - Tokyo
2 programs
RHMS-RTMN/A1 trial
RHMS-RTMN/A1 trial
Active Trials
NCT04499703Completed60Est. Jan 2021
NCT04428242Withdrawn0Est. Jul 2020
Novartis
NovartisBASEL, Switzerland
2 programs
LKA651PHASE_11 trial
MHU650PHASE_11 trial
Active Trials
NCT02867735Completed28Est. Feb 2018
NCT04635800Completed21Est. May 2022
Genentech
GenentechCA - Oceanside
2 programs
Intravitreal injection of ranibizumab .3 dosePHASE_1_21 trial
RanibizumabPHASE_4Monoclonal Antibody1 trial
Active Trials
NCT00407355Completed40Est. Feb 2013
NCT01277302Completed202Est. Oct 2012
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
2 programs
BI 1026706PHASE_21 trial
BI 1815368PHASE_21 trial
Active Trials
NCT02732951Completed105Est. Oct 2017
NCT06962839Recruiting300Est. Sep 2027
Chugai Pharma
Chugai PharmaJapan - Tokyo
2 programs
FaricimabPHASE_3Monoclonal Antibody
FaricimabPHASE_3Monoclonal Antibody
Coordination Pharmaceuticals
1 program
RanibizumabN/AMonoclonal Antibody1 trial
Active Trials
NCT00562406Completed30Est. Sep 2010
GSK
GSKLONDON, United Kingdom
1 program
GSK2798745PHASE_11 trial
Active Trials
NCT04292912Terminated16Est. Apr 2022
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
triamcinolone acetonidePHASE_2
Regeneron
RegeneronTARRYTOWN, NY
1 program
AfliberceptPHASE_3
Roche
RocheSTAVANGER NORWAY, Norway
1 program
FaricimabPHASE_3Monoclonal Antibody

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
AbbVieOZURDEX
AbbViedexamethasone implant
AbbVieOzurdex Intravitreal Injection
GenentechRanibizumab
AbbVieUpdated DEX PS DDS Applicator
Kodiak SciencesKSI-301
Clearside Biomedicalsuprachoroidal CLS-TA
Clearside Biomedicalsuprachoroidal CLS-TA
AbbVieDexamethasone
AbbVie700 μg Dexamethasone
BayerVEGF Trap-Eye
Pfizerpegaptanib sodium
AbbVie700 µg Dexamethasone
AbbVie700 µg Dexamethasone
Boehringer IngelheimBI 1815368

Showing 15 of 37 trials with date data

Clinical Trials (37)

Total enrollment: 6,920 patients across 37 trials

NCT03908307AbbVieOZURDEX

Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in China

Start: Jul 2019Est. completion: Sep 2021150 patients
Phase 4Completed
NCT01903720AbbViedexamethasone implant

A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion

Start: Jul 2013Est. completion: Mar 201571 patients
Phase 4Completed
NCT01870440AbbVieOzurdex Intravitreal Injection

TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema

Start: May 2013Est. completion: Feb 201510 patients
Phase 4Completed
NCT01277302GenentechRanibizumab

A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion

Start: Feb 2011Est. completion: Oct 2012202 patients
Phase 4Completed
NCT04976777AbbVieUpdated DEX PS DDS Applicator

A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina

Start: Oct 2021Est. completion: Feb 202254 patients
Phase 3Completed
NCT04592419Kodiak SciencesKSI-301

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)

Start: Sep 2020Est. completion: Jan 2023568 patients
Phase 3Completed
NCT03203447Clearside Biomedicalsuprachoroidal CLS-TA

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO

Start: Mar 2018Est. completion: Dec 2018325 patients
Phase 3Terminated
NCT02980874Clearside Biomedicalsuprachoroidal CLS-TA

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

Start: Jan 2017Est. completion: Dec 2018460 patients
Phase 3Terminated
NCT02121262AbbVieDexamethasone

A Safety and Efficacy Study of Dexamethasone Versus Laser Photocoagulation in Participants With Diabetic Macular Edema

Start: Jan 2016Est. completion: Nov 2019284 patients
Phase 3Completed
NCT01660802AbbVie700 μg Dexamethasone

Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion (RVO)

Start: Sep 2012Est. completion: May 2014262 patients
Phase 3Completed
NCT01512966BayerVEGF Trap-Eye

Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema)

Start: Jan 2012Est. completion: Sep 201373 patients
Phase 3Completed
NCT01100307Pfizerpegaptanib sodium

A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema

Start: May 2010Est. completion: Aug 2012243 patients
Phase 3Completed
NCT00168298AbbVie700 µg Dexamethasone

A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion

Start: Nov 2004Est. completion: Sep 2008668 patients
Phase 3Completed
NCT00168324AbbVie700 µg Dexamethasone

A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion

Start: Oct 2004Est. completion: Oct 2008599 patients
Phase 3Completed
NCT06962839Boehringer IngelheimBI 1815368

A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema

Start: Jun 2025Est. completion: Sep 2027300 patients
Phase 2Recruiting
NCT02732951Boehringer IngelheimBI 1026706

Safety and Effect on Central Retinal Thickness of BI 1026706 in Patients With Diabetic Macular Edema

Start: Apr 2016Est. completion: Oct 2017105 patients
Phase 2Completed
NCT02303184Clearside Biomedical4 mg CLS-TA

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

Start: Jan 2015Est. completion: Mar 201646 patients
Phase 2Completed
NCT02186119AbbVieabicipar pegol

A Study of Abicipar Pegol in Patients With Diabetic Macular Edema

Start: Jul 2014Est. completion: Jun 2015151 patients
Phase 2Completed
NCT01471054AbbVieOzurdex

Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma

Start: Apr 2014Est. completion: Jul 20156 patients
Phase 2Terminated
NCT01673191AbbVieDexamethasone intravitreal implant

A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus

Start: Nov 2012Est. completion: Dec 201440 patients
Phase 2Completed
NCT01492400AbbViedexamethasone Intravitreal Implant

Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema

Start: Mar 2012Est. completion: Feb 2014363 patients
Phase 2Completed
NCT00782717AlconNepafenac ophthalmic suspension, 0.1%

A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients

Start: Nov 2008Est. completion: Jul 2010263 patients
Phase 2Completed
NCT00692614MSDtriamcinolone acetonide

A Study of MK0140 in Diabetic Patients With Macular Edema (0140-001)

Start: Jun 2008Est. completion: Nov 20082 patients
Phase 2Terminated
NCT01027650AbbVieAGN208397 intravitreal injection

Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)

Start: Mar 2010Est. completion: Feb 2013121 patients
Phase 1/2Completed
NCT00407355GenentechIntravitreal injection of ranibizumab .3 dose

Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions

Start: Jan 2006Est. completion: Feb 201340 patients
Phase 1/2Completed
NCT04635800NovartisMHU650

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients

Start: Dec 2020Est. completion: May 202221 patients
Phase 1Completed
NCT04292912GSKGSK2798745

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema

Start: Sep 2020Est. completion: Apr 202216 patients
Phase 1Terminated
NCT02867735NovartisLKA651

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema

Start: Sep 2016Est. completion: Feb 201828 patients
Phase 1Completed
NCT04499703Kubota VisionRHMS-RTM

Evaluation of the Retinal Health Monitoring System Thickness Module

Start: Nov 2020Est. completion: Jan 202160 patients
N/ACompleted
NCT04428242Kubota VisionRHMS-RTM

Study Evaluating Retinal Health Monitoring System Thickness Module

Start: Apr 2020Est. completion: Jul 20200
N/AWithdrawn
NCT02188173AbbViedexamethasone 700 ㎍ intravitreal implant

An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)

Start: Jul 2014Est. completion: May 2016200 patients
N/ACompleted
NCT01805323AbbVieDexamethasone Intravitreal Implant

A Retrospective Chart Review of OZURDEX® in Patients With Macular Edema

Start: Sep 2012Est. completion: Apr 2013101 patients
N/ACompleted
NCT01571557AbbViedexamethasone 700 ug intravitreal implant

A Safety and Efficacy Study to Assess OZURDEX® in Patients With Macular Oedema Secondary to Retinal Vein Occlusion (RVO)

Start: Apr 2012Est. completion: Jun 2014573 patients
N/ACompleted
NCT01945892AbbVieOzurdex

Dexamethasone-Implant for the Treatment of Macula Edema Due to Irvine Gass Syndrome

Start: Nov 2011Est. completion: Jul 201323 patients
N/ACompleted
NCT01618266AbbViedexamethasone intravitreal implant

Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion

Start: Nov 2011Est. completion: Oct 2014375 patients
N/ACompleted
NCT01445626AbbViedexamethasone intravitreal implant 0.7 mg

A Retrospective Data Collection Study in Patients Receiving Dexamethasone Intravitreal Implant (Ozurdex®) for Macular Oedema Due to Retinal Vein Occlusion (RVO)

Start: Oct 2011Est. completion: Jan 201287 patients
N/ACompleted
NCT00562406Coordination PharmaceuticalsRanibizumab

Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES)

Start: Nov 2007Est. completion: Sep 201030 patients
N/ACompleted

Related Jobs

Principal Medical Writer

4D Molecular Therapeutics4D Molecular Therapeutics
Remote
4d ago
$180K - $202K/yr

Director, Financial Planning and Analysis

4D Molecular Therapeutics4D Molecular Therapeutics
Emeryville, California
5d ago
$237K - $263K/yr

Executive Director, Preclinical and Translational Sciences

4D Molecular Therapeutics4D Molecular Therapeutics
Remote
5d ago
$270K - $342K/yr

Senior Recruiter (Contract)

4D Molecular Therapeutics4D Molecular Therapeutics
Remote
1w ago
$144K - $198K/yr

Clinical Research Associate (Contract)

4D Molecular Therapeutics4D Molecular Therapeutics
Remote
1w ago
$38 - $52/hr

Director, Clinical Quality Assurance (CQA)

4D Molecular Therapeutics4D Molecular Therapeutics
Remote
1w ago
$205K - $235K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

13 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 6,920 patients
20 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.